Business Model and Financial Strategy DecisionsLicensing, M&A, partnering, scaling-up, IPO and m

by GeneOnline
Share To

The pathways are many, the risks are varied, but the choices made early on will be critical to the future success of a growing biotech company. In this session, we have invited industry veterans and heavyweight speakers to advise on making important decisions around business model development and strategy.

Swimming with Sharks: Early Stage Biotechnology Business Models and Financing Strategies

Dr. Carter will give a talk about bioindustry development cycles and introducing the challenges and opportunities for all early-stage companies.


Building a Biotechnology Company through Collaboration, Licensing and M&A

Mr. Grady will address why AstraZeneca set up an innovation center in China while most western big pharma retreated. What strategies, pipelines, or disease areas so far and what can we expect from these strategies?


Dr. Li is a Venture Partner with Lilly Asia Ventures. He was most recently Executive VP and Global Head of Business Development at BeiGene; prior to that, he was VP of Business Development and Licensing at Merck and Executive Director of External R&D at Amgen. With over 21 years of industry experience, he will be sharing his investment strategy and insights.


Dr. McCracken will share his insight regarding Genentech has leveraged academic collaborations, in-licensing, out-licensing, and M&A to discover and bring its innovative medicines to patients.


Session organizer:

Online @ BIO Asia-Taiwan, July 23.
15:40-17:10 Taipei Time

Don’t miss your chance to join thousands of bioindustry professionals from Asia and around the world at BIO Asia–Taiwan 2020 Online + Live!
BIO Asia-Taiwan 2020 Secretariat | | +886-2-7700-3883

© All rights reserved. Collaborate with us:
Related Post
BIO Asia-Taiwan 2022: Looking for the Exit; Startup Considerations and Strategies
BIO Asia-Taiwan 2022: Top iPS Cell Technologies at Affordable Prices – Keynote by Nobel Laureate Shinya Yamanaka
Reinvigorating the Asian Biomedical Ecosystem With BIO Asia-Taiwan 2022
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
Comparing ESG Regulations in the U.S., the U.K., and the EU
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
Scroll to Top